Key result
Medical therapy restores LVEF to ~40% after acute afterload mismatch following ViV TMVR.
Why the study?
Hypotension after valve-in-valve trans-catheter mitral valve replacement complicates post-procedural management, and acute afterload mismatch leading to left ventricular dysfunction after this procedure has been rarely reported.
Case Report (n=1)
No
Abrupt severe left ventricular dysfunction immediately following trans-catheter mitral valve-in-valve replacement can be caused by acute afterload mismatch and is reversible with prompt administration of afterload-reducing agents, inotropes, and diuretics.
Answers are grounded in this paper and cite their sources.
Acute afterload mismatch may cause reversible LV dysfunction after TMVR; extends surgical observations but leaves open prospective validation.
Background Valve-in-valve (ViV) trans-catheter mitral valve replacement (TMVR) is an effective alternative to redo-surgical mitral valve replacement (MVR) in patients with degenerated surgical bioprostheses. Hypotension post-TMVR occurs infrequently and often complicates the post-procedural management. Case summary An 80-year-old male with hypothyroidism and meningioma presented with a 3-month history of dyspnoea, fatigue, and paroxysmal palpitations. He had undergone bioprosthetic mitral and aortic valve replacement 10 years back for rheumatic severe aortic stenosis, moderate mitral stenosis, and mitral regurgitation. Trans-oesophageal echocardiography (TEE) showed bio-prosthetic mitral valve degeneration with severe posteriorly directed eccentric mitral regurgitation, left ventricular (LV) ejection fraction (EF) of 50% and normal aortic prosthesis. He underwent trans-septal, trans-femoral ViV TMVR with 29 mm balloon-expandable valve (Myval, Meril LifeSciences) under TEE guidance without any intra-procedural complications. Thirty minutes after shifting to intensive care, he developed severe LV dysfunction with EF of 10%–15%. Acute afterload mismatch (AM) was diagnosed after ruling out LVOTO, tamponade, device embolization, PVL, and acute coronary syndrome and was successfully managed with nitroglycerine, inotropes, and diuretics, to which he promptly responded within 12 h. At 1-month follow-up, his functional capacity and LVEF (40%) improved significantly with normal prosthesis function. Discussion AM leading to LV dysfunction after surgical MVR has been well described; however, there are very few reports of post-TMVR AM. Our case highlights that an abrupt fall in LV function after TMVR should raise concern for AM, and prompt management with afterload-lowering agents often leads to LV functional recovery.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) conducted a case report in Bioprosthetic mitral valve degeneration with severe mitral regurgitation complicated by post-TMVR acute afterload mismatch and left ventricular dysfunction (n=1). Trans-septal, trans-femoral valve-in-valve trans-catheter mitral valve replacement (29 mm Myval) followed by nitroglycerine, inotropes, and diuretics was evaluated on Left ventricular ejection fraction (LVEF) recovery after acute afterload mismatch. Valve-in-valve TMVR was complicated by acute afterload mismatch reducing LVEF from 50% to 10%–15%, which recovered to 40% at 1 month with nitroglycerine, inotropes, and diuretics.
Synapse has enriched 10 related papers. Consider them for comparative context: